A recent National Institute on Drug Addiction Call to Action focused on expanding methadone treatment access for individuals with opioid use disorder (OUD). One research priority identified was optimal educational and support structures, including training to provide methadone across multiple healthcare settings (e.g., primary care, opioid treatment programs [OTPs], pharmacies) and healthcare workers (HCWs) (e.g., providers, pharmacists). This scoping review sought to better understand HCWs’ knowledge, attitudes, and stigma as it relates to methadone provision.
Methods:
Four databases (PubMed, PsycInfo, CINAHL, Web of Science) were searched for publications between 2010 and 2022 using keywords—methadone, HCW, outpatient setting, knowledge, attitudes, and stigma, focusing on HCWs in general and pharmacists specifically.
Results:
A total of 2,747 articles were identified and 14 met inclusion criteria for review. Settings included OTPs (n = 4), specialty addiction treatment clinics (n = 3), community pharmacies (n = 2), and multiple settings (n = 5). All articles (n = 14) examined methadone-related attitudes. Despite approval of methadone in 1972 to treat OUD, four articles illustrated continued methadone-related stigma held by HCWs. In response to COVID-19-related policy changes allowing methadone take-home flexibility, OTP clinicians expressed a range of attitudes concerning patient risk and potential program liability around diversion and misuse. One article assessing knowledge suggested that, even when most pharmacists correctly answered knowledge questions, a significant minority had misunderstandings that could undermine effective treatment.
Conclusions:
Given the current imbalance between methadone treatment demand and availability, there is a critical need to expand outpatient methadone services. Pharmacists partnering with OTPs represent a logical but underutilized access point. We identified key areas to improve HCWs methadone-related knowledge, attitudes, and stigma. Future research should explore the impact of outpatient pharmacy-OTP and other expansion services, and systematic training, education, and evaluation of methadone-related understanding, including assessment tools to measure knowledge, attitudes, and stigma.
CasillasSM.Patient-level and county-level trends in nonfatal opioid-involved overdose emergency medical services encounters—491 counties, United States, January 2018–March 2022. MMWR Morb Mortal Wkly Rep. 2022;71(34):1073-1080. doi:10.15585/mmwr.mm7134a1
2.
HollandKMJonesCVivolo-KantorAM, et al. Trends in US emergency department visits for mental health, overdose, and violence outcomes before and during the COVID-19 pandemic. JAMA Psychiatry. 2021;78(4):372. doi:10.1001/jamapsychiatry.2020.4402
3.
WeissAJElixhauserABarrettMLSteinerCABaileyMKO’MalleyL.Opioid-related inpatient stays and emergency department visits by state, 2009–2014. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality (US); 2006.
4.
PetersonCXuLMikoszCAFlorenceCMackKA.US hospital discharges documenting patient opioid use disorder without opioid overdose or treatment services, 2011-2015. J Subst Abuse Treat. 2018;92:35-39. doi:10.1016/j.jsat.2018.06.008
5.
Vivolo-KantorAMSethPGladdenRM, et al. Vital signs: trends in Emergency Department visits for suspected opioid overdoses—United States, July 2016-September 2017. MMWR Morb Mortal Wkly Rep. 2018;67(9):279-285. doi:10.15585/mmwr.mm6709e1
6.
Centers for Disease Control and Prevention. 2019 Annual Surveillance Report of Drug-Related Risks and Outcomes—United States Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Accessed December 12, 2023. https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillancereport.pdf.
MurthyVH.Ending the opioid epidemic—A call to action. N Engl J Med. 2016;375(25):2413-2415. doi:10.1056/NEJMp1612578
9.
VolkowNDFriedenTRHydePSChaSS.Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063-2066. doi:10.1056/NEJMp1402780
10.
CrowleyRKirschnerNDunnASBornsteinSS, Health and Public Policy Committee of the American College of Physicians. Health and public policy to facilitate effective prevention and treatment of substance use disorders involving illicit and prescription drugs: an American College of Physicians position paper. Ann Intern Med. 2017;166(10):733-736.
11.
KolodnyACourtwrightDTHwangCS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36(1):559-574.
12.
JaffeJ.From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2):S3-S11. doi:10.1016/S0376-8716(03)00055-3
13.
Institute of Medicine (US) Committee on Federal Regulation of Methadone Treatment. Federal Regulation of Methadone Treatment. In: RettigRAYarmolinskyA, eds. National Academies Press (US); 1995. Accessed November 20, 2023. http://www.ncbi.nlm.nih.gov/books/NBK232108/
14.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. In: MancherMLeshnerAI, eds. Medications for Opioid Use Disorder Save Lives. National Academies Press (US); 2019.
MattickRPBreenCKimberJDavoliM.Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):CD002209. doi:10.1002/14651858.CD002209.pub2
18.
AmatoLDavoliMAperucciCFerriMFaggianoFPmattickR.An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4):321-329. doi:10.1016/j.jsat.2005.02.007
19.
National Academies of Sciences, Engineering, and Medicine; Action Collaborative on Countering the U.S. Opioid Epidemic; Health and Medicine Division; Board on Health Care Services; Board on Health Sciences Policy. In: StroudCPosey NorrisSMBainL, eds. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. National Academies Press (US); 2022.
20.
BerheDFTaxisKHaaijer-RuskampFMMolPGM. Healthcare professionals’ level of medication knowledge in Africa: a systematic review. Br J Clin Pharmacol. 2018;84(12):2729-2746. doi:10.1111/bcp.13746
21.
KeijsersCJPWBrouwersJRBJde WildtDJ, et al. A comparison of medical and pharmacy students’ knowledge and skills of pharmacology and pharmacotherapy. Br J Clin Pharmacol. 2014;78(4):781-788. doi:10.1111/bcp.12396
22.
SimonsenBOJohanssonIDaehlinGKOsvikLMFarupPG.Medication knowledge, certainty, and risk of errors in health care: a cross-sectional study. BMC Health Serv Res. 2011;11:175. doi:10.1186/1472-6963-11-175
23.
EarnshawVSmithLCopenhaverM.Drug Addiction Stigma in the Context of Methadone Maintenance Therapy: an Investigation into Understudied Sources of Stigma. Int J Ment Health Addict. 2013;11(1):110-122. doi:10.1007/s11469-012-9402-5
24.
WooJBhaleraoABaworM, et al. “Don’t Judge a Book by Its Cover”: a qualitative study of methadone patients’ experiences of stigma. Subst Abuse Res Treat. 2017;11:1178221816685087. doi:10.1177/1178221816685087
25.
AnvariMSKleinmanMBMasseyEC, et al. “In their mind, they always felt less than”: the role of peers in shifting stigma as a barrier to opioid use disorder treatment retention. J Subst Abuse Treat. 2022;138:108721. doi:10.1016/j.jsat.2022.108721
26.
HusainJMCromartieDFitzelle-JonesEBrochierABorbaCPCMontalvoC.A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations. J Subst Abuse Treat. 2023;144:108918. doi:10.1016/j.jsat.2022.108918
27.
GoffmanE.Stigma: notes on the Management of Spoiled Identity. Prentice Hall; 1963.
28.
AndersenMMVargaSFolkerAP.On the definition of stigma. J Eval Clin Pract. 2022;28(5):847-853. doi:10.1111/jep.13684
29.
CarlAPasmanEBromanMJListerJJAgiusEReskoSM.Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug Alcohol Depend Rep. 2023;6:100138. doi:10.1016/j.dadr.2023.100138
30.
MajerJMBeasleyCSteckerE, et al. Oxford house residents’ attitudes toward medication assisted treatment use in fellow residents. Community Ment Health J. 2018;54(5):571-577. doi:10.1007/s10597-017-0218-4
31.
BootyMDHarpKBattyEKnudsenHKStatonMOserCB.Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: perspectives from clinicians. J Subst Use Addict Treat. 2023;149:209051. doi:10.1016/j.josat.2023.209051
32.
WoodCADuelloAMilesJ, et al. Acceptance of medications for opioid use disorder in recovery housing programs in Missouri. J Subst Abuse Treat. 2022;138:108747. doi:10.1016/j.jsat.2022.108747
33.
BrownARWaltersJEHarmerBCatesLJonesAE.Non-prescribing clinicians’ treatment orientations and attitudes toward treatments for opioid use disorder: rural differences. J Subst Use Addict Treat. 2023;155:209153. doi:10.1016/j.josat.2023.209153
34.
ListerJJWeaverAEllisJDHimleJALedgerwoodDM.A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46(3):273-288. doi:10.1080/00952990.2019.1694536
35.
RichardELSchalkoffCAPiscalkoHM, et al. “You are not clean until you’re not on anything”: perceptions of medication-assisted treatment in rural Appalachia. Int J Drug Policy. 2020;85:102704. doi:10.1016/j.drugpo.2020.102704
36.
BruceRD.The marketing of methadone: how an effective medication became unpopular. Int J Drug Policy. 2013;24(6):e89-e90. doi:10.1016/j.drugpo.2013.10.006
37.
ThakrarAPPytellJDStollerKBWaltersVWeissRDChanderG.Transitioning off methadone: a qualitative study exploring why patients discontinue methadone treatment for opioid use disorder. J Subst Use Addict Treat. 2023;150:209055. doi:10.1016/j.josat.2023.209055
38.
DuffyPMackridgeAJ.Use and diversion of illicit methadone—under what circumstances does it occur, and potential risks associated with continued use of other substances. J Subst Use. 2014;19(1-2):48-55. doi:10.3109/14659891.2012.734539
JoudreyPJEdelmanEJWangEA.Drive times to opioid treatment programs in urban and rural counties in 5 US states. JAMA. 2019;322(13):1310. doi:10.1001/jama.2019.12562
43.
KleinmanRA.Comparison of driving times to opioid treatment programs and pharmacies in the US. JAMA Psychiatry. 2020;77(11):1-9. doi:10.1001/jamapsychiatry.2020.1624
44.
KleinmanRAMorrisNP.Federal barriers to addressing the opioid epidemic. J Gen Intern Med. 2020;35(4):1304-1306. doi:10.1007/s11606-020-05721-5
45.
QatoDMZenkSWilderJHarringtonRGaskinDAlexanderGC.The availability of pharmacies in the United States: 2007-2015. PLoS One. 2017;12(8):e0183172. doi:10.1371/journal.pone.0183172
46.
JoudreyPJChadiNRoyP, et al. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: a cross-sectional study. Drug Alcohol Depend. 2020;211:107968. doi:10.1016/j.drugalcdep.2020.107968
47.
WuLJohnWSMorseED, et al. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial. Addiction. 2022;117(2):444-456. doi:10.1111/add.15641
48.
JoudreyPJBartGBroonerRK, et al. Article Commentary: research priorities for expanding access to methadone treatment for opioid use disorder in the United States: a National Institute on Drug Abuse Clinical Trials Network Task Force Report. Subst Abuse. 2021;42(3):245-254. doi:10.1080/08897077.2021.1975344
49.
NunesEVKunzKGalanterMO’ConnorPG.Addiction psychiatry and addiction medicine: the evolution of addiction physician specialists. Am J Addict. 2020;29(5):390-400. doi:10.1111/ajad.13068
50.
TriccoACLillieEZarinW, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and Explanation. Ann Intern Med. 2018;169(7):467-473. doi:10.7326/M18-0850
51.
BrideBEAbrahamAJKintzleSRomanPM.Social workers’ knowledge and perceptions of effectiveness and acceptability of medication assisted treatment of substance use disorders. Soc Work Health Care. 2013;52(1):43-58. doi:10.1080/00981389.2012.725457
52.
DavenportESArnettSJNicholsMAMillerML.Indiana community pharmacist preceptors’ knowledge and perceptions of medication-assisted treatment. J Am Pharm Assoc. 2020;60(3):S20.e4-S28.e4. doi:10.1016/j.japh.2020.01.001
KampmanKJarvisM.American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-367. doi:10.1097/ADM.0000000000000166
CroffRHoffmanKAlanis-HirschKFordJMcCartyDSchmidtL.Overcoming barriers to adopting and implementing pharmacotherapy: the medication research partnership. J Behav Health Serv Res. 2019;46(2):330-339. doi:10.1007/s11414-018-9616-9
57.
Snell-RoodCWillgingCShowalterDPetersHPolliniRA.System-level factors shaping the implementation of “hub and spoke” systems to expand MOUD in rural areas. Subst Abuse. 2021;42(4):716-725. doi:10.1080/08897077.2020.1846149
58.
LevanderXAPytellJDStollerKBKorthuisPTChanderG.COVID-19-related policy changes for methadone take-home dosing: a multistate survey of opioid treatment program leadership. Subst Abuse. 2022;43(1):633-639. doi:10.1080/08897077.2021.1986768
59.
EversmanMH.“We Want a Living Solution”: views of harm reduction programs in black U.S. communities. J Ethn Subst Abuse. 2015;14(2):187-207. doi:10.1080/15332640.2014.976803
60.
HunterSBDoppAROberAJUscher-PinesL.Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: a qualitative study. J Subst Abuse Treat. 2021;124:108288. doi:10.1016/j.jsat.2021.108288
61.
MaddenEFChristianBTLagisettyPARayBRSulzerSH.Treatment provider perceptions of take-home methadone regulation before and during COVID-19. Drug Alcohol Depend. 2021;228:109100. doi:10.1016/j.drugalcdep.2021.109100
62.
MitchellSGMonicoLBLertchE, et al. Counseling staff’s views of patient-centered methadone treatment: changing program rules and staff roles. J Behav Health Serv Res. 2018;45(3):506-515. doi:10.1007/s11414-018-9603-1
63.
OberleitnerLMSMaddenLMMuthulingamD, et al. A qualitative investigation of addiction counselors’ perceptions and experiences implementing an open-access model for treating opioid use disorder. J Subst Abuse Treat. 2021;121:108191. doi:10.1016/j.jsat.2020.108191
64.
RoseVJLutnickAKralAH.Feasibility of providing interventions for injection drug users in pharmacy settings: a case study among San Francisco pharmacists. J Psychoactive Drugs. 2014;46(3):226-232. doi:10.1080/02791072.2014.921745
65.
HaffajeeRLAndraka-ChristouBAttermannJCupitoABucheJBeckAJ.A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prev Policy. 2020;15(1):69. doi:10.1186/s13011-020-00312-3
66.
NovickDMSalsitzEAJosephHKreekMJ.Methadone medical maintenance: an early 21st-century perspective. J Addict Dis. 2015;34(2-3):226-237. doi:10.1080/10550887.2015.1059225
67.
GugalaEBriggsOMoczygembaLRBrownCMHillLG.Opioid harm reduction: a scoping review of physician and system-level gaps in knowledge, education, and practice. Subst Abuse. 2022;43(1):972-987. doi:10.1080/08897077.2022.2060423
68.
FiellinDAO’ConnorPG.New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med. 2002;137(8):688-692. doi:10.7326/0003-4819-137-8-200210150-00014
69.
MerrillJO.Policy progress for physician treatment of opiate addiction. J Gen Intern Med. 2002;17(5):361-368. doi:10.1007/s11606-002-0041-6
70.
Kennedy-HendricksAMcGintyEESummersAKrennSFingerhoodMIBarryCL.Effect of exposure to visual campaigns and narrative vignettes on addiction stigma among health care professionals: a randomized clinical trial. JAMA Netw Open. 2022;5(2):e2146971. doi:10.1001/jamanetworkopen.2021.46971
71.
HookerSACrainALLaFranceAB, et al. A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians. Addict Sci Clin Pract. 2023;18(1):10. doi:10.1186/s13722-023-00366-1
72.
CaplehornJRLumleyTSIrwigL.Staff attitudes and retention of patients in methadone maintenance programs. Drug Alcohol Depend. 1998;52(1):57-61. doi:10.1016/s0376-8716(98)00047-7
73.
SmithLRMittalMLWagnerKCopenhaverMMCunninghamCOEarnshawVA.Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS). Addiction. 2019;115(2):354-367. doi:10.1111/add.14799
74.
WuLTMannelliPJohnWSAndersonASchwartzRP.Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff. Subst Abuse Treat Prev Policy. 2023;18(1):55. doi:10.1186/s13011-023-00563-w
75.
SaitzRLarsonMJLaBelleCRichardsonJSametJH.The case for chronic disease management for addiction. J Addict Med. 2008;2(2):55-65. doi:10.1097/ADM.0b013e318166af74
76.
BureshMSternRRastegarD.Treatment of opioid use disorder in primary care. BMJ. 2021;373:n784. doi:10.1136/bmj.n784
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
